Financial Performance - The company's operating revenue for 2021 was RMB 1,297.43 million, an increase of 31.2% compared to RMB 989.01 million in 2020[7] - The profit before tax for 2021 was RMB 95.70 million, up from RMB 74.32 million in 2020[7] - Net profit attributable to shareholders for 2021 was RMB 44.05 million, a decrease from RMB 55.77 million in 2020[7] - The total liabilities as of December 31, 2021, were RMB 1,106.88 million, an increase from RMB 955.55 million in 2020[7] - The company achieved a total revenue of RMB 1,297.4 million in 2021, representing a 31.2% increase compared to 2020, with self-operated hospital revenue at RMB 1,202.8 million, up 28.6%[26] - The gross profit margin for self-operated hospitals improved to 25.4% in 2021 from 25.0% in 2020, with overall gross profit increasing to RMB 329.0 million, a growth of 26.6%[26] - Net profit attributable to shareholders decreased by 21.0% to RMB 44.0 million in 2021 compared to the previous year[26] - The total billing revenue for self-owned hospitals reached RMB 1,230.0 million, an increase of RMB 251.5 million or 25.7% compared to 2020, driven by growth in several hospitals and acquisitions[33] - The gross profit for self-owned hospitals increased by 20.2% to RMB 332.9 million, attributed to an increase in inpatient bed days and average spending per bed day[33] - Inpatient billing revenue was RMB 1,053.7 million, up 24.8% year-on-year, with inpatient bed days increasing by 22.3%[36] - Outpatient billing revenue rose by 31.7% to RMB 176.3 million, driven by a 45.3% increase in outpatient visits[36] Assets and Liabilities - Total assets as of December 31, 2021, were RMB 2,377.97 million, compared to RMB 2,161.28 million in 2020[7] - As of December 31, 2021, accounts receivable increased by 38.4% to RMB 311.8 million, reflecting growth in operating revenue[67] - As of December 31, 2021, the group had no investment properties, down from RMB 107.8 million as of December 31, 2020[69] - Other non-current financial assets increased to RMB 65.8 million as of December 31, 2021, from RMB 57.4 million as of December 31, 2020, reflecting a fair value increase of RMB 8.4 million[70] - Right-of-use assets rose to RMB 257.4 million as of December 31, 2021, up from RMB 232.6 million as of December 31, 2020, due to new lease agreements adding RMB 24.8 million[71] - Accounts payable decreased to RMB 69.2 million as of December 31, 2021, from RMB 72.0 million as of December 31, 2020[74] Operational Expansion - The number of medical institutions operated by the company increased from 24 at the end of 2020 to 27 at the end of 2021[11] - The number of operational beds increased from 7,438 at the end of 2020 to 8,728 at the end of 2021[11] - In 2021, the group expanded its hospital network to 27 hospitals, up from 24 in 2020, with a total of 8,728 operational beds, an increase from 7,438 beds in the previous year[19] - The group reported significant growth in its newly established hospitals, with rapid business scale growth compared to the same period last year[19] - The group successfully integrated acquired hospitals, including Wenzhou Cining Hospital and Changchun Kanglin Psychological Hospital, contributing positively to overall performance during the reporting period[19] - The group is actively developing the elderly rehabilitation medical sector, having acquired Pingyang Chang Geng Yining Hospital and established Cangnan Yining Nursing Center[20] Strategic Initiatives - The company aims to expand its influence in the mental health sector, aligning with national health strategies[9] - The group is focusing on the construction of key projects, including new hospital buildings and renovation projects, to accumulate development momentum for high-quality growth[20] - The group is exploring new business development paths through the construction of an "Internet Mental Health Platform" and integration with upstream pharmaceutical businesses[20] - The group is committed to improving medical service capabilities to meet diverse patient needs, especially in the context of increasing mental health issues[14] - The group is responding to national health strategies aimed at improving mental health services and community rehabilitation systems[15] Governance and Compliance - The company has complied with relevant laws and regulations, including the Mental Health Law and the Basic Medical and Health Promotion Law of the People's Republic of China[102] - The company has complied with the corporate governance code and maintained the minimum public float as required by Hong Kong listing rules[160][161] - The financial statements for the year ended December 31, 2021, were audited by Lixin CPA, following the resignation of PwC due to unresolved audit concerns[164] - The company appointed Lixin as its auditor on January 30, 2022, to fill the temporary vacancy left by PwC until the next annual general meeting[166] - The supervisory board has effectively monitored the company's major policies and decisions, ensuring compliance with relevant laws and regulations[173] - The board consists of seven members, including two executive directors, two non-executive directors, and three independent non-executive directors, in compliance with Hong Kong listing rules[177] Human Resources - Employee compensation for the year was approximately RMB 443.3 million, up from RMB 339.1 million in 2020, with an average salary of RMB 123.6 thousand per year[92] Risks and Challenges - The company faces risks including high public medical insurance payment amounts, a shortage of professional medical personnel, and the potential inability to renew necessary business licenses[24] - The health sector is expected to see significant growth opportunities, driven by increased public awareness of mental health and an aging population, despite facing challenges from economic uncertainties and healthcare reforms[25] Shareholder Information - The company reported a total of 74,600,300 shares issued as of December 31, 2021, comprising 55,260,000 domestic shares and 19,340,000 H shares[131] - Mr. Guan Weili holds 18,350,250 domestic shares, representing approximately 40.07% of the domestic shares and 29.68% of the total issued share capital[131] - Ms. Wang Lianyue also holds 3,794,500 domestic shares, equivalent to approximately 40.07% of the domestic shares and 29.68% of the total issued share capital[131] - Ms. Wang Hongyue owns 3,984,350 domestic shares, which is about 10.46% of the domestic shares and 7.76% of the total issued share capital[131] - Mr. Xu Yongji holds 4,540,000 domestic shares, accounting for approximately 8.22% of the domestic shares and 6.09% of the total issued share capital[131]
康宁医院(02120) - 2022 - 年度财报